Mathieu Chantal, Overbergh Lut
Head of Endocrinology.
Senior Researcher, NAIMIT Consortium, Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.
Eur Endocrinol. 2014 Aug;10(2):100-105. doi: 10.17925/EE.2014.10.02.100. Epub 2014 Aug 28.
NAIMIT (acronym for Natural Immune Modulation for Intervention in Type 1 Diabetes) is a large-scale collaborative programme of the 7th framework from the European Commission. The aim of the consortium is to bring together a group of leading European researchers spanning the field from genetics, through pancreatic beta-cell, dendritic cells and T-cell biology, towards clinical interventions. The ultimate goal is to develop novel and personalised interventional therapies in recent-onset type 1 diabetic patients, with minimal immune system interference, leading to beta-cell protection and restoration, based on a solid understanding of the disease pathogenesis, enabling experimental findings to be adopted for clinical applications.
NAIMIT（1型糖尿病干预的自然免疫调节的首字母缩写）是欧盟委员会第七框架下的一个大规模合作项目。该联盟的目标是汇聚一批欧洲顶尖研究人员，涵盖从遗传学、胰腺β细胞、树突状细胞和T细胞生物学领域，直至临床干预。最终目标是在对疾病发病机制有深入了解的基础上，为近期发病的1型糖尿病患者开发新型个性化干预疗法，对免疫系统干扰最小，实现β细胞保护和恢复，使实验结果能够应用于临床。
